C – Reactive Protein Testing Market

The Global C-Reactive Protein Testing market is expected to reach USD 1.75 billion by 2023 from USD 1.62 billion in 2018, growing at a CAGR of 1.5 % from 2018 to 2023. Growing occurrences of Non Communicable Diseases (NCDs) such as Cardiovascular Diseases, Diabetes and other inflammatory diseases are the major drivers for this market. Point of Care technology for CRP testing is also being used for diagnostic purposes.

North America dominates the C-Reactive Protein Testing market with the U.S. accounting for a major market share. This market is primarily driven by the increasing incidences of chronic NCDs. The Asian market is poised to grow at the highest CAGR during the forecast period owing to increasing use in clinical settings as well as increasing government funding in healthcare.

Prominent players in the C-Reactive Protein Testing  Market are ABCAM (UK), BIOTECHNE (R&D SYSTEMS) (US), F. HOFFMANN-LA ROCHE AG (SWITZERLAND), RANDOX LABORATORIES LTD. (UK), MERCK & CO., INC. (US), THERMO FISHER SCIENTIFIC INC. (US), LIFESPAN BIOSCIENCES, INC. (US), ABAXIS, INC. (US), QUEST DIAGNOSTICS (US) AND SIEMENS HEALTHINEERS (GERMANY).

Scope of the Report

This research report covers the CRP Test market by assay type, application, end user, and geography.

C - Reactive protein Testing Market, by Assay Type

• ELISA
• CLIA
• TURBIDIMETRIC and IMMUNOTURBIDIMETRIC Assay
• Others

C - Reactive protein Testing Market, by Application

• Cardiovascular Diseases
• Inflammatory Bowel Disease
• Rheumatoid Arthritis
• Cancer
• Others

C - Reactive protein Testing Market, by End User

• Hospitals and Clinics
• Diagnostic Laboratories
• Others

C - Reactive Protein Testing Market, by Geography

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
• Rest of the World